Rubicon Organics (ROMJ) Q3 2024 earnings summary

Executive summary

• Achieved record net revenue of $13.5 million in Q3 2024, up 34–35% year-over-year, and $34.5 million for the first nine months, up 15% year-over-year.

• Delivered highest adjusted positive EBITDA for the quarter ($2.0 million), positive for eight of the last nine quarters, and two fiscal years of positive operating cash flow.

• Maintained #1 premium licensed producer status in Canada, leading premium market share across flower, pre-rolls, edibles, and topicals.

• Expanded product portfolio with successful launches in vapes and edibles, with vapes achieving up to 55% national distribution in six months.

• Focused on premium and super-premium segments, leveraging proprietary cultivation and genetics.

Financial highlights

• Q3 2024 net revenue: $13.5 million; nine-month net revenue: $34.5 million; Q3 gross profit: $4.4 million; gross margin: 32–32.4%.

• Adjusted EBITDA: $2.0 million for Q3 2024; positive for eight of last nine quarters.

• Operating cash flow: $0.9 million in Q3 2024; year-to-date $1.1 million; 12 months to Q4 2023: $5.1 million.

• Cash and cash equivalents: $9.8 million as of September 30, 2024; working capital: $9.6 million.

• Included $0.6 million in one-time ERP implementation costs in Adjusted EBITDA for the nine months.

Outlook and guidance

• Expects continued net revenue growth and increased Adjusted EBITDA for 2024, excluding ERP investment.

• Anticipates vapes to contribute over 20% growth on 2023 net revenue by 2025.

• Plans to secure an additional 20% flower capacity in 2025 and enter new international markets.

• Preparing for long-term debt refinancing before year-end 2024 at similar or lower rates.

• Most growth expected from branded products using external capacity, likely resulting in lower gross margins.